Neural Aurora (06681.HK) obtained national authoritative certification: participated in national key scientific and technological projects and was approved as the Beijing Key Laboratory of Digital Medical Treatment for Cognitive Disorders

On December 22, 2025, $BRAINAURORA-B(06681.HK) announced that its wholly-owned subsidiary, Beijing Zhijingling Technology Co., Ltd. (“Zhijingling Tech”), has achieved two major breakthroughs: First, it participated in the application for the national key R&D program “Research on Prevention and Treatment of Cancer, Cardiovascular and Cerebrovascular Diseases, Respiratory and Metabolic Diseases” and, after months of fierce competition among top medical and research institutions in the field, successfully stood out and was officially approved for the project “Establishment and Application of Key Digital Diagnosis and Treatment Technologies for Cognitive Impairment Related to Intracranial Atherosclerotic Stenosis Based on Deep Reasoning Large Models” (Project No.: 2025ZD0546200), which has now been launched. Second, the “Beijing Key Laboratory of Digital Medicine for Cognitive Impairment,” jointly applied for by Zhijingling Tech and Xuanwu Hospital of Capital Medical University, was approved.

These achievements mark the company’s AI-powered digital technology capabilities and industry influence in the field of digital diagnosis and treatment for cognitive impairment, which have been highly recognized at the national and local levels. The company’s technological R&D, clinical translation, and platform construction have entered a new phase.

Launch of National Key Project to Build a New Ecosystem for Digital Diagnosis and Treatment of Cognitive Impairment

Intracranial Atherosclerotic Stenosis (ICAS) has an incidence rate of up to 13% in people over 35 years old in China. The irreversible damage to brain tissue caused by ICAS leads to cognitive impairment characterized by memory decline, language disorders, and executive dysfunction. Despite nearly half of moderate to severe ICAS patients suffering from cognitive impairment, effective early diagnosis and treatment methods are still lacking.

The newly launched national key R&D project focuses on the challenges of diagnosing and treating ICAS-related cognitive impairment. Leveraging interdisciplinary advantages, it will conduct systematic research with core directions including establishing an assessment technology system and deep reasoning prediction models for ICAS-related cognitive impairment, providing tools for early screening, risk prediction, prevention, and intervention, and building a closed-loop management system for ICAS-related cognitive impairment across all scenarios.

It is reported that the project is led by Xuanwu Hospital of Capital Medical University, in collaboration with Peking Union Medical College Hospital, Institute of Psychology of the Chinese Academy of Sciences, Jilin University, Beijing Normal University, and Zhijingling Tech, among others. The research team brings together top experts in neurology, cognitive neuroscience, psychology, and artificial intelligence, and maintains long-term cooperation with leading international research teams. Multiple important achievements published in top journals such as Science and Cell have laid a solid foundation for the project’s implementation.

Approval of Key Laboratory to Strengthen Innovation Hub for Industry-Academia-Research-Medicine Integration

The “Beijing Key Laboratory of Digital Medicine for Cognitive Impairment,” approved during the same period, is jointly established through deep integration of clinical medicine, basic research, technology development, and hardware innovation, forming a collaborative model of “clinical-driven, foundation-supported, software-hardware combined, and translation-oriented.” The laboratory will be jointly built by Zhijingling Tech and Xuanwu Hospital of Capital Medical University, among others, serving as an important scientific research platform for the company’s strategic layout in the field of digital medicine for cognitive impairment.

The laboratory will leverage the advantages of multiple resources, including Neural Aurora’s focus on AI-powered core technology R&D, clinical translation, and industry standard-setting for digital diagnosis and treatment of cognitive impairment. It will establish a high-level academic exchange and talent cultivation platform, promote the deep integration of digital medical technology and clinical diagnosis and treatment, and provide continuous momentum for industry innovation and development.

Multiple Strategic Values Highlighted to Empower Long-Term Development

These two breakthroughs hold profound strategic significance for Neural Aurora. In terms of scientific research capabilities and industry standing, participation in national key projects and the co-construction of key laboratories will significantly enhance the company’s top-level research design and major project management capabilities. Through collaborative efforts with top-tier teams, the R&D team’s clinical thinking and complex problem-solving abilities will be further refined, enabling the continuous production of high-quality academic achievements through the deep integration model of “industry-academia-research-medicine” and strengthening the company’s academic reputation and industry authority in the field of “digital therapeutics.” At the core technology level, leveraging high-quality clinical data obtained through project collaborations and deep integration with AI large model technology, the company will optimize the precision and personalization of cognitive assessment and intervention solutions, build cross-modal correlation analysis and prediction models from “cerebrovascular lesions” to “cognitive function,” and advance technology from “functional training” to “etiological diagnosis and comprehensive management,” thereby constructing higher technical barriers. In terms of business development, with the authoritative endorsement of national-level projects, the company will further deepen cooperation with top medical institutions, strengthen its research collaboration network covering over 200 hospitals, shorten the market introduction cycle for products, accelerate the expansion into vast professional medical markets such as neurology, geriatrics, and cardiovascular, and drive business model upgrades and scale expansion.

Tan Zheng, Chairman of Neural Aurora, stated: “The company’s undertaking of the national key R&D program and the approval of the Beijing Key Laboratory fully demonstrate its technological leadership in the field of digital diagnosis and treatment for cognitive impairment, marking an important milestone in the company’s development. As a typical treatment method in the field of digital diagnosis and treatment for neurocognitive disorders in China, the launch of this project signifies its elevation to the level of national scientific research strategy and reflects the high recognition of the company’s AI technology capabilities and scientific research potential by the nation and Beijing. In the future, Neural Aurora will continue to focus on technological innovation and clinical translation in the field of digital diagnosis and treatment for cognitive impairment, advance related research work, and contribute to the establishment of an internationally leading cognitive impairment diagnosis and treatment technology system, supporting the implementation of the ‘Healthy China’ strategy.”